Table 1.
Group |
Treatments |
n | Adenoma (%) | Carcinoma (%) | Total (%) | ||
HBVx gene | AFB1 | CT | |||||
1 | - | - | - | 40 | 0 (0) | 0 (0) | 0 (0) |
2 | + | - | - | 10 | 0 (0) | 0 (0) | 0 (0) |
3 | - | + | - | 20 | 1 (5.0) | 0 (0) | 1 (5.0) |
4 | + | + | - | 11 | 1 (9.1) | 0 (0) | 1 (9.1) |
HBVx gene | AFB1 | MC-LR | |||||
5 | - | - | + | 26 | 1 (3.9) | 0 (0) | 1 (3.9) |
6 | + | - | + | 11 | 0 (0) | 0 (0) | 0 (0) |
7 | - | + | + | 21 | 2 (9.5) | 2 (9.5) | 4 (19.0)a |
8 | + | + | + | 15 | 2 (13.3) | 1 (6.7) | 3 (20.0)a |
HBVx gene | AFB1 | NOD | |||||
9 | - | - | + | 26 | 0 (0) | 0 (0) | 0 (0) |
10 | + | - | + | 11 | 0 (0) | 0 (0) | 0 (0) |
11 | - | + | + | 9 | 2 (22.2) | 1 (11.1) | 3 (33.3)b,c |
12 | + | + | + | 11 | 4 (36.4) | 0 (0) | 4 (36.4)d,e,f |
MC-LR: Microcystin-LR; NOD: nodularin. aP < 0.05 vs group 1, bP < 0.01 vs group 1, cP < 0.05 vs group 9, dP < 0.01 vs group 1, eP < 0.05 vs group 3, fP < 0.01 vs group 9.